All Trials

A Phase 1 Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SHY-ONC6 in Participants With Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with measurable advanced or metastatic solid tumors that have progressed on, or are unsuitable or intolerant of, standard therapy receive once-daily oral SHY-ONC6. SHY-ONC6 is a small-molecule proteasome inhibitor targeting selected AAA+ ATPases in the 19S regulatory particle to disrupt ubiquitinated protein processing and promote apoptosis.

ClinicalTrials.gov ID: NCT07705334

A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory unresectable or metastatic solid tumors and an accessible injectable lesion, with expansion cohorts in cutaneous squamous-cell carcinoma, melanoma, head and neck squamous-cell carcinoma, NSCLC, and triple-negative breast cancer. Patients receive intratumoral N17350 every 2 weeks, a recombinant mutant porcine pancreatic elastase targeting the neutrophil elastase/ELANE pathway and designed to induce immunogenic tumor-cell death.

ClinicalTrials.gov ID: NCT07339176

Phase 1/2, Open-Label, Multicenter, Dose Escalation and Expansion Study of BHB810 in Participants With Advanced Gastric and Gastroesophageal Junction Adenocarcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced CDH17-positive gastric or gastroesophageal-junction adenocarcinoma after failure of or ineligibility for standard/curative therapy receive intravenous BHB810 every 2 weeks. BHB810 is a CDH17-directed antibody–drug conjugate that delivers the microtubule-disrupting payload MMAE to CDH17-expressing tumor cells.

ClinicalTrials.gov ID: NCT07529808

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Enrichment, and Dose-Expansion Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of BLU-924 (SAR449336) as Monotherapy and Combination Therapy in Participants With Advanced Pancreatic Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer Harboring KRAS Mutations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with previously treated metastatic pancreatic ductal adenocarcinoma, NSCLC, or colorectal cancer harboring KRAS G12C/D/V/A/S or G13D mutations, measurable disease, and ECOG 0–1 are eligible. Participants receive oral once-daily BLU-924 (SAR449336), an investigational pan-KRAS small-molecule inhibitor, as monotherapy.

ClinicalTrials.gov ID: NCT07629960

Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with untreated, measurable microsatellite-stable metastatic colorectal cancer and ECOG 0–1 receive first-line FOLFOX6 plus investigational SAR445877, a bifunctional anti–PD-1/IL-15 fusion protein that activates cytotoxic T and NK cells; bevacizumab is included during dose escalation but is not listed in the expansion regimen.

ClinicalTrials.gov ID: NCT07500298

Phase I, Open-Label Study of Autologous Mutant KRAS and ILT4-Redirected T-cell Receptor Cells (TCR1188-ABC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with HLA-A*11:01-positive, KRAS G12V-mutant metastatic pancreatic, biliary, colorectal, or non-small cell lung cancer after standard therapy receive fludarabine/cyclophosphamide lymphodepletion followed by a single infusion of autologous TCR-engineered T cells recognizing HLA-A*11:01-presented KRAS G12V and targeting ILT4/LILRB2-positive immunosuppressive cells; prophylactic tocilizumab is given on day 2.

ClinicalTrials.gov ID: NCT07594067

A Phase 1a/1b Open Label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of DBC-664 in Adult Patients With Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable recurrent, locally advanced, or metastatic solid tumors, including endometrial and ovarian cancers, receive DBC-664 monotherapy in dose-escalation or expansion cohorts. DBC-664 is an investigational biologic with an undisclosed molecular target and mechanism of action.

ClinicalTrials.gov ID: NCT07705035

A Phase 1/2 Study of DS-8201a (NSC# 807708) in Children, Adolescents, or Young Adults With Recurrent Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Children and young adults aged 2–39 years with measurable, unresectable recurrent or refractory Wilms tumor or desmoplastic small round cell tumor receive IV trastuzumab deruxtecan every 21 days. Trastuzumab deruxtecan is a HER2-directed antibody-drug conjugate that delivers a topoisomerase I inhibitor payload to HER2-expressing tumor cells.

ClinicalTrials.gov ID: NCT04616560

A Phase 1 Study Of LNK001 (Dual ENPP3/CAIX AND-gate CAR T Cell Therapy) In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic clear-cell–component renal cell carcinoma, ECOG 0–1, measurable disease, and ≥50% tumor CAIX expression after prior PD-1/PD-L1 inhibitor and tyrosine kinase inhibitor therapy receive fludarabine/cyclophosphamide lymphodepletion followed by autologous LNK001 CAR-T cells. LNK001 uses a dual-receptor CAIX/ENPP3 Boolean AND-gate designed to activate preferentially against tumor cells coexpressing both targets.

ClinicalTrials.gov ID: NCT07564232

An Open-Label, Multicenter, Phase 1a/1b, Dose Escalation/Dose Expansion Clinical Trial of Theranostic Pair PD-32766D, a 64Cu-Labeled Peptide and PD-32766T, an 225Ac-Labeled Peptide Targeting Carbonic Anhydrase IX in Adult Participants With Relapsed or Refractory Clear Cell Renal Cell Carcinoma Who Have Progressed From or Could Not be Administered Due to Medical Unsuitability or Limited Access to All Standard of Care Therapies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic clear cell renal cell carcinoma who have exhausted, cannot medically receive, or lack access to standard therapies and have CAIX-positive uptake on PD-32766D PET imaging receive intravenous PD-32766T, an actinium-225–labeled CAIX-targeting peptide that delivers localized alpha radiation. Treatment is dose-escalated and expanded for up to six cycles.

ClinicalTrials.gov ID: NCT07688187